BCM
CLDX icon

Bridgeway Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Bridgeway Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-50,200
Closed -$83K – 1316
2020
Q1 		$83K Sell
50,200
-27,100
-35% -$61.2K ﹤0.01% 1191
2019
Q4 		$172K Sell
77,300
-70,000
-48% -$162K ﹤0.01% 1214
2019
Q3 		$314K Sell
147,300
-57,600
-28% -$133K ﹤0.01% 1088
2019
Q2 		$549K Buy
204,900
+81,200
+66% +$276K 0.01% 949
2019
Q1 		$609K Buy
+123,700
New +$651K 0.01% 964

Other funds holding CLDX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Bridgeway Capital Management's CLDX Position: Q2 2020 in Review

Bridgeway Capital Management sold out of Celldex Therapeutics (CLDX) in Q2 2020, closing a stake of 50,200 shares — an estimated $83K sold.

Bridgeway Capital Management first reported a position in CLDX in Q1 2019 and held it in 5 quarters. The position peaked at $609K in Q1 2019. 76 funds tracked by Wall St. Rank hold CLDX as of Q2 2020.

  • Bridgeway Capital Management reported no remaining Celldex Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Bridgeway Capital Management sold 50,200 Celldex Therapeutics shares in Q2 2020, an estimated $83K.
  • Bridgeway Capital Management first reported a position in Celldex Therapeutics in Q1 2019 and held it in 5 quarters.
  • Bridgeway Capital Management's Celldex Therapeutics position peaked at $609K in Q1 2019.
  • 76 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2020.

Based on Bridgeway Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.